BUZZ - Vaxcyte shares soar following successful late-stage clinical trial for pneumococcal vaccine

October 5 - ** Vaxcyte (PCVX.O) shares surged 26% in pre-market trading to $71.17

** Vaxcyte stated that its 31-valent pneumonia vaccine VAX-31 met all primary endpoints in a late-stage clinical trial (link) and generated an immune response comparable to or stronger than that of Pfizer's PFE.N Prevnar 20 and Merck's MRK.N Capvaxive

** The safety and tolerability of the vaccine were comparable to existing vaccines

** Vaxcyte expects to obtain results from two additional late-stage clinical trials in the first half of 2027 and plans to submit a marketing application to the FDA in the first half of 2028

** As of the close of the previous trading day, the stock had risen 22.4% year-to-date

(To facilitate non-English speakers, Reuters provides automated translations of its reports into several other languages. Automated translation may be inaccurate or may fail to capture the intended meaning, and Reuters makes no guarantee regarding the accuracy of the translated text. Automated translation is provided solely for the convenience of readers. Reuters accepts no liability for any damages or losses arising from the use of this automated translation function.)